EANM guidelines on the use of [18F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders.

Cristina Nanni, Christophe M Deroose, Sona Balogova, Constantin Lapa, Nadia Withofs, Manil Subesinghe, Bastien Jamet, Elena Zamagni, Davide Ippolito, Michel Delforge, Francoise Kraeber-Bodéré

Research output: Contribution to journalArticlepeer-review

Abstract

We provide updated guidance and standards for the indication, acquisition, and interpretation of [18F]FDG PET/CT for plasma cell disorders. Procedures and characteristics are reported and different scenarios for the clinical use of [18F]FDG PET/CT are discussed. This document provides clinicians and technicians with the best available evidence to support the implementation of [18F]FDG PET/CT imaging in routine practice and future research.

Original languageEnglish
Pages (from-to)171-192
Number of pages22
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume52
Issue number1
Early online date29 Aug 2024
DOIs
Publication statusPublished - Dec 2024

Fingerprint

Dive into the research topics of 'EANM guidelines on the use of [18F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders.'. Together they form a unique fingerprint.

Cite this